Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany.
Journal
HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
06
12
2021
accepted:
29
04
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
12
7
2022
Statut:
epublish
Résumé
The aim was to assess the incremental costs of chimeric antigen receptor (CAR) T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel) compared with standard of care in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) from the German third-party payer perspective. A budget impact model was established over a 6-year period. Estimation of the third-line population: partitioned survival model based on outcome data from peer-reviewed literature, a top-down approach based on population forecasts, and age-standardized incidences. Cost data were derived from the controlling department of a tertiary hospital and a German cost-of-illness study. In the scenario analysis, the budget impact of treating second-line DLBCL patients was calculated. One-way deterministic sensitivity analyses were conducted to test the robustness of the model. For the period 2021-2026, 788-867 (minimum population, min) and 1,068-1,177 (maximum population, max) adult third-line r/r DLBCL patients were estimated. The budget impact ranged from €39,419,562; €53,426,514 (min; max) in year 0 to €122,104,097; €165,763,001 (min; max) in year 5. The scenario analysis resulted in a budget impact of €65,987,823; €89,558,611 (min; max) and €204,485,031; €277,567,601 (min; max) for years 0 and 5, respectively. This budget impact analysis showed a significant but reasonable financial burden associated with CAR T-cell therapy for a limited number of patients requiring individualized care. Further, this study presents challenges and future needs in data acquisition associated with cost analysis in personalized medicine. For comprehensive economic discussions, complementary cost-effectiveness analyses are required to determine the value of innovative therapies for r/r DLBCL.
Identifiants
pubmed: 35813101
doi: 10.1097/HS9.0000000000000736
pmc: PMC9257301
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e736Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Références
N Engl J Med. 2022 Feb 17;386(7):629-639
pubmed: 34904798
Pharmacotherapy. 2017 Mar;37(3):334-345
pubmed: 28079265
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
J Clin Oncol. 2005 Jun 20;23(18):4117-26
pubmed: 15867204
Blood Adv. 2020 Oct 13;4(19):4669-4678
pubmed: 33002134
J Clin Oncol. 2010 Sep 20;28(27):4184-90
pubmed: 20660832
Hemasphere. 2021 Jan 28;5(2):e524
pubmed: 33880433
Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):474-482
pubmed: 35033478
Lancet Oncol. 2020 Feb;21(2):e104-e116
pubmed: 32007196
J Clin Oncol. 2019 Aug 20;37(24):2105-2119
pubmed: 31157579
N Engl J Med. 2021 Feb 18;384(7):673-674
pubmed: 33596362
Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
Gene Ther. 2020 Dec;27(12):537-544
pubmed: 31024072
J Med Econ. 2018 Dec;21(12):1238-1245
pubmed: 30260711
Blood Adv. 2020 May 12;4(9):2011-2017
pubmed: 32396614
Br J Cancer. 2015 Apr 28;112(9):1575-84
pubmed: 25867256
N Engl J Med. 2022 Feb 17;386(7):640-654
pubmed: 34891224
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
JAMA Netw Open. 2019 Feb 1;2(2):e190035
pubmed: 30794298
Value Health. 2014 Jan-Feb;17(1):5-14
pubmed: 24438712
Value Health. 2007 Sep-Oct;10(5):336-47
pubmed: 17888098
Hematology Am Soc Hematol Educ Program. 2011;2011:498-505
pubmed: 22160081
Eur J Health Econ. 2020 Dec;21(9):1351-1361
pubmed: 32654072
Nat Med. 2021 Aug;27(8):1311
pubmed: 34385703
J Clin Oncol. 2017 Feb 10;35(5):544-551
pubmed: 28029326
Haematologica. 2013 Nov;98(11):1726-31
pubmed: 23753028